U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07875920) titled 'Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation' on Sept. 30.
Brief Summary: This is a single-arm, multicenter, open-label, Phase 1a/1b dose-escalation and dose-expansion study designed to evaluate the safety, preliminary antitumor activity, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of NW-301V, an autologous TCR-T cell therapy, in Chinese adult participants with advanced malignant solid tumors harboring a KRAS G12V mutation.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Colorectal Adenocarcin...